TY  - GEN
AU  - Pek,M
AU  - Yatim,S M J M
AU  - Chen,Y
AU  - Li,J
AU  - Gong,M
AU  - Jiang,X
AU  - Zhang,F
AU  - Zheng,J
AU  - Wu,X
AU  - Yu,Q
TI  - Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
SN  - 1476-5594
PY  - 2017///1013
KW  - Animals
KW  - Benzamides
KW  - pharmacology
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - drug effects
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Cyclin-Dependent Kinase 4
KW  - antagonists & inhibitors
KW  - Cyclin-Dependent Kinase 6
KW  - Diphenylamine
KW  - analogs & derivatives
KW  - Female
KW  - Gene Expression Profiling
KW  - HCT116 Cells
KW  - HT29 Cells
KW  - Humans
KW  - MAP Kinase Kinase Kinases
KW  - Mice
KW  - Mice, Inbred NOD
KW  - Mice, SCID
KW  - Molecular Targeted Therapy
KW  - Piperazines
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins p21(ras)
KW  - genetics
KW  - Pyridines
KW  - Random Allocation
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1038/onc.2017.120
ER  -